亚洲肥胖与非酒精性脂肪性肝病的新趋势
本文综述亚洲肥胖的流行病学趋势,重点讨论非酒精性脂肪性肝病(NAFLD)。亚洲NAFLD人口患病率约25%,与非肥胖人群中的NAFLD(即「瘦型」NAFLD)日益受到关注;生活方式干预仍是基石,但长期维持减重困难,亚洲患者在药物试验中代表性不足。
要点
- 亚洲NAFLD人口患病率约25%,与许多西方国家相似。
- 体重指数低于25kg/m2的亚洲人中约8-19%存在NAFLD。
- 生活方式干预是肥胖和NAFLD管理的基石,但长期维持减重困难。
核心结论
- 亚洲肥胖和NAFLD的流行病学趋势日益显著,瘦型NAFLD值得关注,未来研究应确定亚洲肥胖和NAFLD的最佳管理策略。
研究设计与样本
- 综述文章,回顾亚洲肥胖的流行病学趋势,重点关注NAFLD。
主要发现
- 亚洲NAFLD人口患病率约25%,与许多西方国家相似。
- 继发于NAFLD的肝细胞癌和终末期肝病虽仍不常见,但呈上升趋势。
- 体重指数低于25kg/m2的亚洲人中约8-19%存在NAFLD,常被描述为「瘦型」或「非肥胖型」NAFLD。
- 中心性肥胖、胰岛素抵抗和体重增加是主要危险因素,PNPLA3多态性等遗传易感性在非肥胖人群NAFLD发展中似乎更重要。
关键数值与推荐
- 亚洲NAFLD人口患病率约25%。
- 体重指数低于25kg/m2的亚洲人中约8-19%存在NAFLD。
临床怎么用
- 生活方式干预仍是肥胖和NAFLD管理的基石,但少数患者能实现充分减重,长期维持体重者更少。
- 药物制剂已进入脂肪性肝炎的III期研发,但亚洲患者在多数药物试验中代表性不足。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Traditionally, obesity and its related diseases have been considered a problem in Western countries. However, in the past two decades, urbanisation in many Asian countries has led to a sedentary lifestyle and overnutrition, setting the stage for the epidemic of obesity. This article reviews the epidemiological trend of obesity in Asia, with special emphasis on the emerging condition of non-alcoholic fatty liver disease (NAFLD). Currently, the population prevalence of NAFLD in Asia is around 25%, like many Western countries. While hepatocellular carcinoma and end-stage liver disease secondary to NAFLD remain uncommon, a rising trend has emerged. Around 8-19% of Asians with body mass indexes less than 25kg/m2 are also found to have NAFLD, a condition often described as "lean" or "non-obese" NAFLD. Although this condition is generally less severe than that in more obese patients, steatohepatitis and fibrotic disease are well recognized. Central adiposity, insulin resistance and weight gain are major risk factors, and genetic predisposition, such as the PNPLA3 polymorphism appears to be more important in the development of NAFLD in the non-obese population. Lifestyle modification remains the cornerstone of management for obesity and NAFLD, but few patients can achieve adequate weight reduction and even fewer can maintain the weight in the long run. While pharmacological agents have entered phase III development for steatohepatitis, Asian patients are under-represented in most drug trials. Future studies should define the optimal management of obesity and NAFLD in Asia.
引用
- Fan JG, Kim SU, Wong VW, et al. New trends on obesity and NAFLD in Asia. J Hepatol. 2017. PMID: 28642059. doi:10.1016/j.jhep.2017.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。